A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Metagenomi (NASDAQ:MGX – Get Free Report) had its price objective lowered by stock analysts at Wells Fargo & Company from $25 ...

Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

Advancements in genome editing, particularly CRISPR, are reshaping precision biology, driving innovations in medicine, agriculture, and synthetic biology.

Shortly after this publication, Bogdanove struck up a collaboration with Daniel Voytas, a plant geneticist at the University ...

After hours: March 19 at 7:55:34 PM EDT Loading Chart for MGX ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

The Diagnostic Specialty Enzymes Market was valued at US$ 1.0 billion in 2022 and is projected to grow at a CAGR of 6.9% from ...

Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo ...